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Abstract
Background: Major depression is a disorder that significantly worsens a patient’s morbidity and mortality. The
association of depression and diabetes is well documented and has clinical impact in diabetes treatment’s
outcome. Patients usually aren’t evaluated initially by a psychiatrist, so it is important that non-psychiatrists learn to
evaluate major depression and its impact.
Conclusions: Major depression can and should be evaluated on a routine clinical assessment. Depression’s impact
on the patients’ quality of life, productivity and social interactions is well documented. The initial diagnosis of
depression should lead to its prompt treatment, and it has to be emphasized that the incorrect treatment can lead
to worsening of the condition, relapses, recurrences or even chronification of major depression.
Introduction
In this approach for non-psychiatrists, we have to begin
with the definition of sadness. According to the The
American Heritage Dictionary of the English Language,
Fourth Edition, sadness (or a sad state) is: 1) Affected or
characterized by sorrow or unhappiness; 2) Expressive
of sorrow or unhappiness; 3) Causing sorrow or gloom,
depressing; 4) Deplorable, sorry; 5) Dark-hued, somber.
Depression is a syndrome whose signs and symptoms
remain for a period of weeks or months. There is also
an important impairment of the usual functions of the
individual, i.e., people change their behavior regarding
work, personal relationships and themselves[1].
T h em o s tr e c e n td i a g n o s t i cc r i t e r i aa d o p t e db yt h e
American Association of Psychiatry[2] are described in
Appendix 1.
It is important to emphasize, for those who are not
used to dealing with depression on a regular basis, that
depression is not just an increase in the intensity or a
different quality of sadness, but rather a state that will
develop into other complications, such as the ones men-
tioned in Appendix 1. The presence of depression’s
symptoms is not enough (A), and we need to evaluate
the functional impact on the individual’s routine (B), the
exclusion of triggering factors such as the use of
depressive substances or clinical conditions (C) and dis-
card the occurrence of a Mourning situation (D).
The prevalence of a major episode of depression
throughout life, according to large studies conducted in
the USA and in Europe varied from 5 to 17%[3-8]. In
our country, considering that there are 180 million Bra-
zilians according to the latest census by IBGE (Brazilian
Institute of Geography and Statistics), estimates show
that 30 million Brazilians will go through a depressive
episode. It’s important to emphasize that general practi-
tioners and neurologists are usually the types of physi-
cians initially visited.
The importance of discussing the diagnosis of depres-
sion for endocrinologists is the frequent association of
depression and diabetes. Several studies have proven
such association[9]. Depression has already been asso-
ciated with hypoglycemia[10], complications related to
diabetes[11], as well as the perception of functional lim-
itations caused by diabetes[12]. A recent Brazilian study
assessing type 2 diabetic patients found not only ele-
vated prevalence of depression, but also a positive corre-
lation between the severity of the depressive condition
and the severity of symmetrical distal diabetic poly-
neuropathy presented by patients[13].
It has already been demonstrated that the levels of
depression in diabetic patients are at least twice as high
as people without chronic diseases[9], the prevalence of
depression in diabetic patients may be ≥ 40%[14], and
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the depressive episode or favor recurrences[15].
Over the last decade depression started being studied
as one of the etiological factors of diabetes[16], and
some studies proved that depression is a predictor of
the later occurrence of diabetes[17,18]. In the general
population, depression is responsible for worsening
morbidity and mortality, even in the absence of diabetes
[19]. A study showed that depression would be an
important risk factor for microvascular disease, macro-
vascular disease, loss of autonomy and even mortality
due to diabetes[20]. From this study, the existence of a
synergic effect between depression and diabetes was
postulated, i.e., the effect of both conditions together
would be higher than the sum of the effects of each[21].
Considering the implications of comorbidity between
depression and diabetes, it is indispensable to assess its
occurrence carefully in diabetic patients. The clinical
implications of depressive conditions are evident, and
the absence of treatment or improper treatment increase
the risk to a magnitude similar to the risk presented by
untreated or improperly treated increased blood pres-
sure[22].
Unfortunately, studies demonstrate that depression is
underdiagnosed, particularlyi nd i a b e t i cp a t i e n t s .I ti s
estimated that only one third of depressed diabetic
patients are properly diagnosed[23]. It is important to
emphasize that proper diagnosis and treatment may lead
to the remission of the depressive condition, and also to
a decrease in the morbidity and mortality risks.
Nowadays, there are over 45 different drugs available
for treating depression, allowing for different options
and interactions. Unfortunately, the most prescribed
drugs are not antidepressants, as patients usually get to
the non-specialist’s office and receive a prescription of
benzodiazepinic drugs so that they “stop bothering the
physician”. There is a wide range of therapeutical possi-
bilities and this allows us to treat the person, not the
disease. Depression occurs twice as much in women as
in men, and there might be a diagnostic confusion
around different conditions, from premenstrual dys-
phoria (former PMS) to premenopausal syndrome and
general anxiety syndromes. We cannot call sadness
depression, nor can we treat sadness.
We have several hypotheses for the etiology of depres-
sion:
1) biological factors, having antidepressants and their
action on the brain neurotransmission, as well as
hormonal factors implying the depression genesis.
2) genetic factors, as studies point to risks two or
three times higher in first-degree family members
with depression. However, studies with homozy-
gotic twins have not proven a concordance of
100%, which allows us to conclude that psychoso-
cial factors are important[24-27].
3) psychosocial factors and the lifestyle adopted by
the person are among the determining factors:
leisure, physical activities versus inactivity, smok-
ing, diet, time spent with the family and time for
their individual hobbies.
The natural progression of depression usually is its
appearance in the third decade of life, and it may occur
at any age. Depressive disorders may start from 5 to 60
years of age. The symptoms develop over weeks and
remain for months until they evolve to the impairment
of one’s functions, which initially goes unnoticed by the
p e r s o n ,o rb yt h e i rf a m i l y .W eh a v eo b t a i n e di n c r e a s i n g
evidence that the conditions which do not receive
proper treatment tend to become chronic.
Nowadays, we consider depression a disease of inter-
mittent chronicity, which results in high economic cost
to the Health System. There is a concept created by the
University of Harvard along with World Health Organi-
zation (WHO) called “Disability Adjusted Life Year”
(DALY)[28], based on the concept that the differences
in ranking disability or death should be by age and gen-
der, not income, culture, location or social class, in an
attempt to standardize morbimortality data globally
s i n c ee v e r y o n ei nt h ew o r l dh a st h er i g h tt oh a v et h e
best possible life expectancy. To calculate DALY, the
criteria considered were years of life lost by death, and
years of life lost due to disability by diseases or traumas.
Data from the World Health Organization[29] for the
year of 2004 are found in Table 1. Depression is not
only a very frequent disease, but also a cause of strong
disability to people.
The estimated cost of depression in the USA is
approximately 81.5 billion dollars per year, with an
annual loss of productivity of 32 billion dollars[30]. It
has been observed that the increase in annual
Table 1 Leading Causes of Burden of Disease in the
World, 2004[29]
DALYs %
1. Lower respiratory infections 6,2
2. Diarrhoeal diseases 4,8
3. Depression 4,3
4. Ischaemic heart disease 4,1
5. HIV/AIDS 3,8
6. Cerebrovascular disease 3,1
7. Prematurity, low birth weight 2,9
8. Birth asphyxia, birth trauma 2,7
9. Road traffic accidents 2,7
10. Neonatal infections and other 2,7
Mezzasalma Diabetology & Metabolic Syndrome 2010, 2:9
http://www.dmsjournal.com/content/2/1/9
Page 2 of 6productivity after treating the employee’s depression is
around U$ 1.800[31]. There are no cost data about
depression for the Brazilian population. Generally,
depressed patients use the health system and present
more medical and psychiatric comorbidities. Depression
is the greatest cause of disability from 15 to 44 years of
age, according to WHO data for the year 2004[32].
Risk Factors for Major Depression:
1. Gender: the female gender has two times more
depression than the male gender;
2. Age: from 20 to 40 years old;
3. Social and economic factors, such as unemploy-
ment and underemployment;
4. Psychosocial factors such as marital state, i.e.,
divorced, widows, widowers or single individuals
have higher risk of developing a depressive condi-
tion. Living in urban areas, negative life events such
as the loss of cherished ones, or common daily news
may be important stress factors.
It is important to remember the possible differential
diagnoses, which are general and neurological medical
conditions, pharmacological agents, other mood disor-
ders, adjustment disorder with depressed mood, mainly
in children and teenagers.
In order to understand why depression and anxiety
coexist in over 70% of the cases, if we analyze the symp-
toms presented there is a huge intersection[33]. Symp-
toms exclusive to depression are depressed mood,
anedonia (losing pleasure in previously pleasant activ-
ities), appetite changes, libido changes, decrease in moti-
vation and suicidal ideation. Symptoms exclusive to
anxiety are hyperexcitability, compulsive rituals and
agoraphobia (fear of crowds or open spaces and even of
“feeling bad”). There are many symptoms common to
both: sensation of fear, apprehension, chronic pains, gas-
trointestinal symptoms, psychomotor excitement, diffi-
culty of concentration, change in the sleep pattern,
fatigue and energy levels, so comorbidities of depression
and anxiety conditions are very common.
Treatment
T h ec h o i c eo fa n t i d e p r e s s a n t si sb a s e do nt h ep a t i e n t
profile as well as liver, kidney and cardiovascular safety,
as different drugs have different side effects and it is
best to personalize the treatment. The analysis of drug
interactions and side effects of other medications is very
important, as well as the assessment of other pathologies
the patient presents, and the action mechanism of the
chosen antidepressant, the drug cost and tolerability.
Generally, antidepressants have very similar efficacy. In
Table 2 we have a list with the main antidepressant
groups available in Brazil.
Regarding the evolution of the treatment, we have the
Kupfer curve[34], which demonstrates how a depressed
individual evolves over time. It can be seen in Figure 1.
An individual was normal and asymptomatic, but
starts presenting symptoms, evolving to a depressive
condition, with a depressive syndrome. In this acute
phase, the treatment starts and a response is observed;
however, such response might stop and symptoms
might keep occurring - this is when a chronic condition
is installed. This condition is very difficult to be solved.
The treatment aims to bring the individual back to
“normalcy”, i.e., leading the patient to complete recovery
from symptoms by reaching remission. Another problem
that might be encountered is when there is an improve-
ment of 80 to 90% but the patient still presents symp-
toms, and as such they would not be completely
recovered; this must also be avoided.
Once remission is reached, a continuation treatment
must be made which lasts approximately for six months
after the first depressive episode, and from one to two
years in case of multiple episodes, as there is a high risk
of relapse even during the treatment with regular medi-
cation use. The risk of relapse in the first six months, if
treatment is interrupted, is approximately 80%. As pre-
viously described, the impact of depression is high from
the economic point of view, which is objectively measur-
able, as well as the subjective point of view, and it must
be avoided.
After this continuation period, the individual may be
considered recovered to go on with the maintenance
stage. Even then there might be later recurrence, i.e.,
after three months, an asymptomatic individual may
present a depressive episode again, so it is considered
another episode of depression, not the same.
It is recommended to start the treatment always with
low doses and increase them progressively in order to
minimize side effects and allow the patient to adjust to
the treatment. The ideal action is to keep the full dose
of antidepressants for all stages of the treatment, as long
as it is well tolerated by the patient.
Regarding psychotherapy, we have three types whose
efficacy is documented in literature: 1) cognitive therapy;
2) behavioral therapy; and 3) interpersonal therapy. Psy-
chotherapy must be always integrated to psychiatric fol-
low-up and with other treatments.
Complementary treatments such as the practice of
sports, yoga, relaxation techniques and meditation, have
their efficacy documented in clinical studies revealing an
improvement in depressive conditions after a change in
lifestyle to include the practice of physical activities,
even studies with yoga techniques.
In conclusion, we must remember that depression is a
public health issue all over the world, causing severe
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Drug Class and Active Ingredient Usual average dose for adults(mg/day) Sedation Anticholinergic Action Orthostatic Hypotension
Tricyclic Antidepressants (TCAs)
A
Imipramine 150-200 Moderate Moderate High
Amitriptyline 150-200 High Very high Moderate
Nortriptyline 75-100 Moderate Moderate Lowest of TCAs
Clomipramine 150-200 High High Low
Tetracyclic Antidepressants
A
Maprotiline 150-200 Moderate Moderate Low
Monoaminoxidase Inhibitors (MAOIs)
Tranilcipromine 30 - Very low High
Selective serotonin reuptake inhibitors (SSRIs)
Fluoxetine 20-60 Very low None Very low
Paroxetine 20-40 Low Low None
Sertraline 100-150 Low None None
Citalopram 20-40 Low None None
Fluvoxamine 50-150 Low None None
Escitalopram 10-20 Low None None
Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Venlafaxine 75-225 Low None Very low
B
Duloxetine 60 Low Very low Very low
Serotonin-norepinephrine-dopamine-reuptake-inhibitors (SNDRI)
Bupropion
C 300 Low Very low Very low
Norepinephrine reuptake inhibitor (NRI);
Reboxetine 8-10 Very low Very low Very low
Noradrenergic and specific serotonergic antidepressant (NaSSA).
Mirtazapine 30-45 High Moderate Low
Serotonin reuptake inhibitors and serotinin antagonist (SARI)
Trazodone
D 150-400 High Very low Moderate
A - All cyclic antidepressants have elevated arrhythmogenic potential;
B - Venlafaxin causes dose-dependant blood pressure increase in some individuals;
C - Bupropion reduces convulsive threshold significantly, and it must be avoided in patients with history of syncopes and seizures;
D - Trazodone is associated with cardiac arrhythmia and priapism
Figure 1 Kupfer Curve.
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of the main causes of suicide worldwide.
To answer the question “Can depression be diagnosed
in a routine clinical evaluation?” The answer is: depres-
sion can and must be diagnosed in a routine clinical
evaluation, because that is what we, psychiatrists, do:
diagnose depression in routine visits to our practice.
In order to track depression at the endocrinologist’s
office, it is important to assess the patient’s mood: both
the presence of unmotivated sadness and the loss of
pleasure in previously pleasant activities, as well as
changes in vegetative functions: sleep, appetite and
libido. Changes in these functions do not only allow the
diagnosis of depression, but they also allow us to assess
its evolution, relapse and recurrence.
Appendix 1: Diagnostic Criteria for Major
Depressive Episode, adapted from DSM-IV-TR
A. At least five of the symptoms below must be
present during the same two-week period, almost
every day, representing a change from the pre-
vious function standard of the individual. One of
the symptoms must be mandatorily number (1) or
(2) as follows:
1. depressed humor most of the day;
2. accentuated decrease in interest or pleasure
in all or almost all activities most of the day;
3. significant weight loss or gain while not on a
diet (e.g., more than 5% of body weight in 1
month), or decrease or increase in appetite;
4. insomnia or hypersomnia;
5. excitement or psychomotor retardation;
6. fatigue or energy loss;
7. feeling of uselessness or excessive or improper
guilt;
8. diminished ability of thinking or concentrat-
ing, or indecision;
9. recurrent thoughts of death (not only fear of
dying), recurrent suicidal ideation without a spe-
cific plan, suicide attempt or specific plan to
commit suicide.
B. The symptoms cause clinically significant suf-
fering or damage in social or occupational func-
tion, or in other important areas in the
individual’s life.
C. The symptoms are not due to direct physiolo-
gical effects of a substance (e.g., drug abuse or
medication) or a general medical condition (e.g.:
hypothyroidism).
D. The symptoms are not better explained by
Mourning (i.e., followed by the loss of loved ones,
symptoms remain for more than 2 months), or
are characterized by accentuated functional
damage, morbid concern about devaluation,
suicidal ideation, psychotic symptoms or psycho-
motor retardation.
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